Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrclinonc.2017.148PMID 28925994PMCID PMC6733403
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells.

  2017cited by this paper
• Malignancy-associated haemophagocytic lymphohistiocytosis in adults.

  2017cited by this paper
• An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma.

  2017cited by this paper
• Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

  2017cited by this paper
• Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis

  2017cited by this paper
• “Race” to the Finish Line

  2017cited by this paper
• Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells.

  2017cited by this paper
• HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B‐NHL TREATED WITH THE CD19‐DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001)

  2017cited by this paper
• GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS

  2017cited by this paper
• Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

  2017cited by this paper
• AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1

  2017cited by this paper
• Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

  2017cited by this paper
• Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

  2016cited by this paper
• Toxicities of chimeric antigen receptor T cells: recognition and management.

  2016cited by this paper
• Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

  2016cited by this paper
• Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

  2016cited by this paper
• T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

  2016cited by this paper
• A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration

  2016cited by this paper
• Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

  2016cited by this paper
• Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes

  2016cited by this paper
• IL-6 pathway in the liver: From physiopathology to therapy.

  2016cited by this paper
• Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

  2016cited by this paper
• Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.

  2016cited by this paper
• Toxicity and management in CAR T-cell therapy

  2016cited by this paper
• Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

  2016cited by this paper
• Nonconvulsive status epilepticus in adults — insights into the invisible

  2016cited by this paper
• CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

  2016cited by this paper
• Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

  2016cited by this paper
• CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

  2016cited by this paper
• Improving the safety of T-Cell therapies using an inducible caspase-9 gene.

  2016cited by this paper
• A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

  2016cited by this paper
• Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS

  2016cited by this paper
• Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

  2016cited by this paper
• Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

  2016cited by this paper
• Driving gene-engineered T cell immunotherapy of cancer

  2016cited by this paper
• Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.

  2016cited by this paper
• Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

  2016cited by this paper
• Driving CAR T-cells forward

  2016cited by this paper
• FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease

  2015cited by this paper
• How I treat hemophagocytic lymphohistiocytosis in the adult patient.

  2015cited by this paper
• Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Adoptive cellular therapy: A race to the finish line

  2015cited by this paper
• CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

  2015cited by this paper
• A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH

  2015cited by this paper
• Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

  2015cited by this paper
• Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

  2015cited by this paper
• Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

  2014cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Current concepts in the diagnosis and management of cytokine release syndrome.

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

  2014cited by this paper
• Exploiting the curative potential of adoptive T‐cell therapy for cancer

  2014cited by this paper
• Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans.

  2014cited by this paper
• Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

  2014cited by this paper
• Adult haemophagocytic syndrome.

  2014cited by this paper
• Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

  2013cited by this paper
• Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

  2013cited by this paper
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

  2013cited by this paper
• Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

  2013cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

  2012cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• The pro- and anti-inflammatory properties of the cytokine interleukin-6.

  2011cited by this paper
• T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

  2011cited by this paper
• PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.

  2011cited by this paper
• How I treat hemophagocytic lymphohistiocytosis.

  2011cited by this paper
• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.

  2011cited by this paper
• A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

  2011cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Tocilizumab for rheumatoid arthritis.

  2010cited by this paper
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

  2010cited by this paper
• Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

  2010cited by this paper
• ▼Tocilizumab for rheumatoid arthritis

  2009cited by this paper
• Vasopressin versus norepinephrine infusion in patients with septic shock.

  2008cited by this paper
• Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

  2008cited by this paper
• Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

  2008cited by this paper
• HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

  2007cited by this paper
• Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

  2006cited by this paper
• Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.

  2005cited by this paper
• Nonconvulsive status epilepticus: Epilepsy Research Foundation workshop reports.

  2005cited by this paper
• CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice

  2004cited by this paper
• Characterization of CD20-Transduced T Lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host Disease

  2004cited by this paper
• An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder.

  2004cited by this paper
• C-reactive protein: a critical update.

  2003cited by this paper
• Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells.

  2002cited by this paper
• A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease.

  2001cited by this paper
• Levetiracetam: A Novel Antiepileptic Drug

  2001cited by this paper
• Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures.

  1998cited by this paper
• Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes

  1996cited by this paper
• Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor.

  1993cited by this paper
• DEPARTMENT OF HEALTH & HUMAN SERVICES

  1991cited by this paper

• The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma

  2026cites this paper
• Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?

  2026cites this paper
• Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

  2026cites this paper
• Incidence, Recurrence, Timing, and Economic Impact of Infections After CAR T-Cell Therapy: A Real-World Analysis from MarketScan Database.

  2026cites this paper
• Cytokine storm

  2026cites this paper
• CAR-engineered cell therapies: current understandings and future perspectives

  2026cites this paper
• Neuronal injury biomarkers GFAP and neurofilament light chains (NfL) are associated with neurotoxicity and endothelial dysfunction in adult patients treated with antiCD19 CART cells

  2026cites this paper
• Tailored strategies for improved control of CAR-T cells in multiple myeloma

  2026cites this paper
• Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives.

  2026cites this paper
• Unraveling the potential of targeting methionine metabolism in cancer.

  2026cites this paper
• Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma.

  2026cites this paper
• Integrating CAR-T therapy with PD-1/PD-L1 blockade: Mechanisms, synergy, and optimized strategies in NSCLC

  2026cites this paper
• Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion

  2026cites this paper
• Frontiers of cytokine engineering in CAR cell therapy for cancer

  2026cites this paper
• Microbiome-Modulated Immunotherapy in Oncology: Current Applications and Future Prospects.

  2026cites this paper
• Brain Microstructural Damage as Potential Biomarker of Immune Cell‐Associated Neurotoxicity Syndrome

  2026influential citation
• The Berlin-Hannover ICANS severity assessment–a novel bedside test to evaluate CAR T-cell-associated neurotoxicity

  2026cites this paper
• Generation of TCRγδ + T cells from human embryonic stem cells

  2026cites this paper
• Yeast Surface Display Meets Immunotherapy: Unlocking the Potential of T Cells

  2026cites this paper
• Case Report: Safety analysis of blinatumomab consolidation therapy in two cases of acute B-cell lymphoblastic leukemia in complete remission complicated with immune effector cell-associated neurotoxicity syndrome

  2026cites this paper
• Toxicities associated with CAR-T therapy compared with standard treatments in hematologic malignancies: a systematic review and meta-analysis.

  2026cites this paper
• Association between Patient-reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-cell Therapy and Clinical Outcomes.

  2026cites this paper
• Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.

  2026cites this paper
• Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

  2026cites this paper
• CAR‐T cell therapy: Advancements in clinical applications and laboratory testing

  2026cites this paper
• Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy.

  2026cites this paper
• CAR-T cells in the treatment of neurological autoimmune diseases

  2026cites this paper
• Nano-/nanobio-technology-enhanced CAR-T cell therapy: engineering the next generation of immunotherapies

  2026cites this paper
• The gut microbiota–brain–CAR T cell axis: a systematic review of gut microbiome modulation and its impact on neurological complications and treatment responses in CAR T cell therapy

  2026cites this paper
• Case Report: A case of heart failure recovery after non-ischemic cardiomyopathy following chimeric antigen receptor T-cell therapy

  2026cites this paper
• Drug-Induced Pulmonary Toxicity in the Era of Immunotherapy and Biologics: A Narrative Review of Mechanism, Diagnosis, and Management.

  2026cites this paper
• Current status and perspective of off-the-shelf CAR-T cells in cancer immunotherapy.

  2026cites this paper
• Acute Kidney Injury and Electrolyte Disorders Following Chimeric Antigen Receptor T-cell (CAR T-cell) Therapy in Adults With Hematologic Malignancies: A Retrospective Study

  2026cites this paper
• Precision immunotherapy with CAR-T cells in pediatric B-cell acute lymphoblastic leukemia: advances and unanswered challenges

  2026cites this paper
• Uncovering the Adaptive Tumor Immunity Interactions from a Single-Cell Level.

  2026cites this paper
• The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy.

  2026cites this paper
• Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma

  2026cites this paper
• Venous Thromboembolism in Aggressive B‐Cell Lymphoma Patients Treated with CD19 CAR‐T Therapy: Single‐Institution Study

  2026cites this paper
• T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy.

  2026cites this paper
• The avatar principle: exosomal dynamics guiding tumor adaptation and next-generation therapeutic strategies

  2026cites this paper
• Anticorps bispécifiques : l’autre forme d’immunothérapie en hématologie

  2026cites this paper
• CAR‐Cell Therapy for Autoimmune Diseases: From the Laboratory to Clinical Practice

  2026cites this paper
• PAST, PRESENT and FUTURE OF LUPUS NEPHRITIS.

  2026cites this paper
• Implementation of CAR-T cell therapy in outpatient settings: a critical review of current literature regarding health outcomes, benefits, challenges, and future directions.

  2026cites this paper
• Outpatient Versus Inpatient Axicabtagene Ciloleucel CAR T-Cell Therapy in Non-Hodgkin's Lymphoma: Insights from a US Multicenter Transplant and Cellular Therapy Network.

  2026cites this paper
• Thermal sonogenetics for adoptive cell transfer therapy.

  2026cites this paper
• In Vivo CAR-T Therapies-A New Era of Programmable Immunity.

  2026cites this paper
• Navigating Ethical Challenges in CAR-T Treatment.

  2026cites this paper
• The effect of monoclonal antibodies on the reactivation of herpesvirus infections and transplant failure in children in the early period after allogeneic hematopoietic stem cell transplantation

  2026cites this paper
• Neurologic Complications of Cancer and Its Treatment.

  2026cites this paper
• Guarding the heart in the era of immunotherapies: insights for cardio-oncology practice

  2026cites this paper
• Saudi experts statement on advancing multiple myeloma treatment: the evolving role of bispecific antibodies

  2026cites this paper
• T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer

  2025cites this paper
• Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study

  2025cites this paper
• RNA epigenetic modifications as dynamic biomarkers in cancer: from mechanisms to clinical translation

  2025cites this paper
• In vivo CAR engineering for immunotherapy

  2025cites this paper
• 2024 International Academy of Toxicologic Pathology (IATP) Satellite Symposium: New Approach Methodologies (NAMs) for Neurotoxicity Assessment and Regulatory Perspectives

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• Inpatient Rehabilitation Outcomes of Cancer Patients After Chimeric Antigen Receptor T-cell Therapy.

  2025cites this paper
• Chimeric antigen receptor T cell immunotherapy-associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review)

  2025influential citation
• Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies.

  2025cites this paper
• Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells

  2025cites this paper
• Advances in T Cell-Based Cancer Immunotherapy: From Fundamental Mechanisms to Clinical Prospects.

  2025cites this paper
• Pathology and treatment for prostate cancer: Based on prostate stem cells and cell therapy

  2025cites this paper
• Emerging trends in clinical allogeneic CAR cell therapy.

  2025cites this paper
• Research trends in CAR-T cell therapy: A comprehensive bibliometric analysis highlighting cardiovascular toxicity and clinical implications

  2025cites this paper
• Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma

  2025cites this paper
• Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy

  2025cites this paper
• Frequently Asked Questions on Imaging in Chimeric Antigen Receptor T-Cell Therapy Clinical Trials

  2025cites this paper
• Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma

  2025cites this paper
• European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring

  2025cites this paper
• EEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapy

  2025influential citation
• Bidirectional Communication Between the Innate and Adaptive Immune Systems

  2025cites this paper
• CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy

  2025cites this paper
• State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment

  2025cites this paper
• Deep insight into cytokine storm: from pathogenesis to treatment

  2025cites this paper
• Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study

  2025cites this paper
• Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

  2025influential citation
• The impact of obesity and its related underlying diseases on cytokine release syndrome and the efficacy of CAR-T therapy in treating B-cell malignancies

  2025cites this paper
• Immunotherapy in chronic lymphocytic leukemia: advances and challenges

  2025cites this paper
• Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells

  2025cites this paper
• Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy

  2025cites this paper
• Trained autologous cytotoxic T-cells derived from PBMCs or splenocytes for immunotherapy of neuroblastoma

  2025cites this paper
• Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

  2025cites this paper
• Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

  2025cites this paper
• Strategies for Altering Delivery Technologies to Optimize CAR Therapy

  2025cites this paper
• Tumoricidal potential of binary therapy in lymphoma: Role of DC-NK cross-talk and checkpoint inhibitors.

  2025cites this paper
• The Role of the Tumor Microenvironment (TME) in Advancing Cancer Therapies: Immune System Interactions, Tumor-Infiltrating Lymphocytes (TILs), and the Role of Exosomes and Inflammasomes

  2025cites this paper
• Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer

  2025cites this paper
• Immune effector cell-associated neurotoxicity syndrome (ICANS)

  2025cites this paper
• Unravelling the modified T cell receptor through Gen-Next CAR T cell therapy in Glioblastoma: Current status and future challenges.

  2025cites this paper
• Steroid hormones as modulators of anti-tumoural immunity

  2025cites this paper
• Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations

  2025cites this paper
• The clinical landscape of CAR-engineered unconventional T cells.

  2025cites this paper
• Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy

  2025cites this paper
• Hemoadsorption as a Supportive Strategy for Severe Toxicity Associated With Chimeric Antigen Receptor T-Cell Therapy: A Case Series

  2025cites this paper
• Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment

  2025cites this paper
• CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses

  2025cites this paper
• Acute Symptomatic Seizures During CAR T-Cell Therapy for Hematologic Malignancies

  2025cites this paper
• Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study.

  2025cites this paper